The world’s first intranasal Covid vaccine, developed by Bharat Biotech, received regulatory approvals for restricted emergency use in Indian adults on Tuesday, boosting the national response to SARS-CoV-2 virus.
Bharatâs COVID-19 shot 81% effective, based on Indian drug makerâs data
March 4, 2021 | 6:28 pm
BENGALURU â Bharat Biotechâs vaccine showed 81% efficacy in preventing symptomatic COVID-19 in an interim analysis of a late-stage trial in India, it said on Wednesday, a major boost for the shot shunned by some due to a lack of such data.
The positive result also brightens prospects for sales overseas, with the vaccine, Indiaâs first successful homemade COVID-19 shot, already attracting interest from more than 40 countries, according to the firm.
âCOVAXIN demonstrates high clinical efficacy trend against COVID-19 but also significant immunogenicity against the rapidly emerging variants,â Bharat Biotech Chairman Krishna Ella said in a statement, referring to its vaccine.